Exogenus Therapeutics
Business Services · Portugal · 1-10 Employees
View Company Info for Free
Overview
Headquarters
Biocant Park Núcleo 04 Lote 2, Cantanhed...Phone Number
+351 231419043Website
www.exogenus-t.comRevenue
<$5 MillionIndustry
About Exogenus Therapeutics
Is Exogenus Therapeutics your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Earning: See what the market has to say on Exogenus Therapeutics recently announced quarterly report
Click to see if Exogenus Therapeutics had a recent Job posting/layoffs
Exogenus Therapeutics, which may be a good buyer, showed buying intent in Masked Content Topic
Funding: Get notified immidiatlly once Exogenus Therapeutics has new funding data
Product Launch: Get notified when Exogenus Therapeutics launches new products
Check out if Exogenus Therapeutics is spiking on competitors!
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Website visits: Recent activity has been detected on your website
Congratulate Masked Content for being promoted to Masked Content at Exogenus Therapeutics
Check if Exogenus Therapeutics has recently received funding, and reach out quickly before it becomes old news!
Recommended Actions
Reach out to Masked Content who joined Exogenus Therapeutics as Masked Content
Find 2 more new buyers
Company Profile Activity
Activity Insights
Exogenus Therapeutics is experiencing very low activity levels compared to other companies in the Business Services sector.
What does this means?
Exogenus Therapeutics is drawing exceptional interest within the Business Services industry, suggesting notable developments or strong market momentum, learn more about Exogenus Therapeutics.
Exogenus Therapeutics Tech Stack
A closer look at the technologies used by Exogenus Therapeutics
Top Business Services Companies
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Exogenus Therapeutics
Exogenus Therapeutics is a Portuguese biotech company focused on the development and commercialization of extracellular vesicles and nanoparticles to address significant healthcare challenges. Their lead product, Exo-101, derived from umbilical cord blood, exhibits regenerative, anti-inflammatory, and immunomodulatory properties, targeting patients... Read More